ClinicalTrials.gg
RecruitingNCT07482020Updated Mar 19, 2026

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

A Phase 2 interventional study of SGLT-2 inhibitors and Placebo in Atrial Fibrillation (AF) and Hypertension, sponsored by Huashan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Huashan Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation — 9 open to participants now, 10 under way, 5 of them phase 3. A drug class: SGLT2 inhibitors · Atrial Fibrillation.

Planned enrollment
13th of 15
66 · median 280
Started
2025
with 2 others
Phase 2
Only one
of the 15
Registered
13th of 15
by date
Lead sponsor
1 of 15
Huashan Hospital

Among the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, this one is the 13th largest by planned enrollment, is one of 3 that started in 2025, is the only one in phase 2, and was the 13th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

9 of the 15 studies testing SGLT2 inhibitors in Atrial Fibrillation are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About SGLT2 inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing SGLT2 inhibitors in Atrial Fibrillation, or all of them as a file.
02

Study summary

Heart failure is the most important clinical endpoint event in atrial fibrillation (AF). Patients with AF complicated by heart failure have a significantly higher risk of all-cause mortality and cardiovascular mortality compared to those without heart failure. Abnormal left atrial function is an important mechanism leading to the occurrence of AF-related heart failure. Therefore, it is essential to find drugs that can improve left atrial function to prevent heart failure in patients with AF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are important drugs for regulating metabolic abnormalities. Studies have found that these drugs also reduce the risk of new-onset AF in patients with heart failure. Thus, the investigators hypothesize that SGLT2i may be able to regulate left atrial function.

This study is a multicenter randomized controlled trial using three-dimensional speckle tracking echocardiography to investigate whether SGLT2i can improve left atrial function and prevent heart failure in patients with paroxysmal AF who have hypertension and metabolic disorders, compared to placebo. The investigators also observed the effects of SGLT2i on cardiovascular and metabolic risk factors. The investigator team has a solid foundation in the field of cardiovascular metabolism, having completed the evaluation of left atrial function in paroxysmal AF using three-dimensional speckle tracking technology over the past three years. This study is the first to propose that SGLT2i can improve left atrial function in paroxysmal AF patients with metabolic abnormalities, which is of great significance for preventing heart failure in this type of AF.

Read the detailed description
  1. Research Methods: This study adopts a multicenter, randomized, placebo-controlled approach, utilizing three-dimensional speckle tracking technology to evaluate the left atrial function of enrolled subjects.
  2. Research Objectives: Compared with placebo, to observe whether empagliflozin (10mg qd) can improve the left atrial function of patients with paroxysmal atrial fibrillation (AF) who have hypertension and metabolic disorders.
  3. Research Endpoints:

    • Primary Endpoint: Using three-dimensional speckle tracking technology to evaluate the changes in left atrial function of subjects in the empagliflozin group and the placebo group at enrollment and after 12 months of follow-up.
    • Evaluation Methods for Primary Endpoint: The left atrial function evaluation of all subjects from all centers will be completed in the echocardiography room of Huashan Hospital. This examination will be conducted in a blinded manner by two experienced echocardiography physicians to assess the left atrial function of the patients, and another two echocardiography physicians will analyze the parameters in a blinded manner.
    • Parameters of Left Atrial Function Changes: Left atrial ejection fraction, left atrial ejection volume, left atrial maximum volume, left atrial minimum volume, left atrial pre-systolic volume, left atrial maximum volume index, peak left atrial longitudinal strain, early diastolic left atrial longitudinal strain, late diastolic left atrial longitudinal strain, peak left atrial circumferential strain, early diastolic left atrial circumferential strain, and late diastolic left atrial circumferential strain.
    • Secondary Endpoint 1: Record events of subjects visiting or being hospitalized due to heart failure during the follow-up period. This endpoint includes patients who present with symptoms such as dyspnea, fatigue, and orthopnea during the follow-up period, and have an NT-proBNP level greater than 300pg/ml detected in the emergency department, outpatient clinic, or inpatient department, with a documented diagnosis.
    • Secondary Endpoint 2: Record the changes in cardiovascular and metabolic risk factors of patients at enrollment and after 12 months of follow-up: blood pressure, blood glucose, uric acid, body weight, and blood lipids. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.
  4. Randomization and Blinding Arrangements: Use random numbers to randomize the enrolled patients into groups; blind two echocardiography physicians who assess the left atrial function of the subjects and two echocardiography physicians who analyze the left atrial function parameters; blind the subjects; and blind the researchers.
  5. Follow-up Medication Use:

    • Experimental Drug: Dapagliflozin 10mg qd, to be used continuously for 12 months.
    • Placebo Drug: A placebo with the same specifications, odor, and color as dapagliflozin, to be used continuously for 12 months.
  6. Follow-up Duration: 12 months. At enrollment and at the 12th month of follow-up, use three-dimensional speckle tracking technology to complete the left atrial function (evaluated in sinus rhythm) examination of the subjects, and complete the biochemical examinations of blood pressure, blood glucose, blood lipids, body weight, uric acid, etc. Record events of subjects visiting or being hospitalized due to heart failure during the follow-up period.
  7. Inclusion Criteria:

    • Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database.
    • Patients with paroxysmal AF confirmed by 12-lead electrocardiogram, 24-hour Holter monitoring, or handheld electrocardiogram devices.
    • Patients with hypertension who have already started antihypertensive treatment.
    • Patients with diabetes who have already started antidiabetic treatment, or patients with prediabetes who have not received antidiabetic treatment but have an HbA1c level within the range of 6.1-6.4% in the past three months.
  8. Exclusion Criteria:

    • Atrial fibrillation caused by severe mitral stenosis.
    • Atrial fibrillation with severe mitral regurgitation and severe tricuspid regurgitation.
    • Patients who have been clinically diagnosed with heart failure (heart failure with preserved ejection fraction or heart failure with reduced ejection fraction).
    • Special types of cardiomyopathy: amyloid cardiomyopathy, Fabry disease, muscular dystrophy, hypertrophic obstructive cardiomyopathy, etc.
    • Patients with a history of myocardial infarction within the past three months.
    • Pregnant women.
  9. Withdrawal Criteria:

    • Patients who cannot undergo echocardiography according to the follow-up schedule after enrollment.
    • Patients who cannot take medication on time after enrollment.
    • Subjects who are unwilling or unable to continue participating in the trial.
    • Subjects who are found to be ineligible for enrollment or meet any exclusion criteria after enrollment.
    • Subjects who experience intolerable adverse events or serious adverse events, and the researcher determines that the risks of continuing to participate in the trial outweigh the benefits for the subject.
    • Subjects who are lost to follow-up.
  10. Sample Size Calculation: Since there are no previous data on the application of SGLT2i in patients with paroxysmal AF, based on the investigators' preliminary experimental results, the difference in left atrial function between patients with paroxysmal AF and healthy patients is as follows: left atrial reservoir function longitudinal strain, 16.1±5.41 in the paroxysmal AF group vs. 20.5±6.55 in the healthy control group. Referring to this parameter, with a power of 0.8 and α of 0.05, the sample size for this study is calculated using statistical formulas as: N=60, with N=30 in each group. Considering a 10% dropout rate, the total number of cases is N=66, with N=33 in each group.
  11. Research Process: Applicable to all centers

    • Introduce the study to patients who meet the above criteria, and those who agree to join will sign the informed consent form.
    • After obtaining informed consent, generate random numbers for randomization into groups.
    • After determining the groups, before administering the medication, complete the baseline left atrial function examination and the examination of cardiovascular and metabolic risk factors, including blood pressure, blood glucose, blood lipids, uric acid, body weight, etc.
    • Administer medication according to the randomized groups.
    • Conduct a telephone follow-up with patients once a month to record medication use, occurrence of heart failure events, and occurrence of adverse events.
    • At the 12th month, conduct another evaluation of left atrial function and examination of cardiovascular and metabolic risk factors.
  12. Measurement Methods and Techniques for the Main Observation Indicators in This Study

    • To avoid measurement bias in the study, all echocardiography examinations of subjects enrolled in all centers will be completed in the echocardiography room of the main hospital of Huashan Hospital.
    • Two experienced echocardiography physicians will collect left atrial data from patients, and another two echocardiography physicians will perform statistical analysis of the data on an offline analysis workstation. All four echocardiography physicians will be blinded.
    • Left Atrial Structure and Function: Firstly, two experienced echocardiography physicians will use the Vivid E95 machine equipped with probes of frequencies M5S 3.5-5MHz and Vivid7 3V 2-4MHz (GE Vingmed Ultrasound, Horten, Norway) to collect three-dimensional speckle images from the enrolled subjects in a blinded manner. All collected images will be imported into the dedicated offline analysis workstation provided by the manufacturer (EchoPAC version 2.0; GE Vingmed Ultrasound), and two echocardiography physicians will perform four-dimensional automatic left atrial quantification (4D Auto LAQ) analysis in a blinded manner.
    • Left Ventricular Parameters: Simultaneously, collect left ventricular parameters including left ventricular end-systolic volume, left ventricular end-diastolic diameter, LVEF assessed by Simpson's method, and E wave, A wave, E/A ratio, or E/e' assessed by pulsed Doppler or tissue Doppler.
    • Assessment of Heart Failure Occurrence: Record events of subjects visiting the outpatient clinic, emergency department, or being hospitalized due to heart failure during the follow-up period. This endpoint includes patients who present with symptoms such as dyspnea, fatigue, and orthopnea during the follow-up period, and have an NT-proBNP level greater than 300pg/ml detected in the emergency department, outpatient clinic, or inpatient department, and are diagnosed with heart failure with a documented diagnosis.
    • Collection of Cardiovascular and Metabolic Abnormality Parameters: At enrollment and after 12 months of follow-up, collect body weight, height, waist circumference, systolic blood pressure, diastolic blood pressure, heart rate, 24-hour ambulatory blood pressure, fasting blood glucose, insulin, C-peptide
03

Conditions studied

  • Atrial Fibrillation (AF)
  • Hypertension

Keywords

  • SGLT2 inhibitor
  • atrial fibrillation
  • hypertension
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patients aged 18-80 years, treated in the outpatient or inpatient departments of each research center and included in the AF database.

      • Patients with paroxysmal AF confirmed by 12-lead , 24-hour Holter monitoring, or handheld electrocardiogram devices.
      • Patients with hypertension who have already started antihypertensive treatment.
      • Patients with diabetes who have already started antidiabetic treatment, or patients with prediabetes who have not received antidiabetic treatment but have an level within the range of 6.1-6.4% in the past three months.

Exclusion criteria

Exclusion Criteria:

    • Atrial fibrillation caused by severe mitral stenosis.

      • Atrial fibrillation with severe mitral regurgitation and severe tricuspid regurgitation.
      • Patients who have been clinically diagnosed with heart failure (heart failure with preserved or heart failure with reduced ejection fraction).
      • Special types of cardiomyopathy: amyloid cardiomyopathy, Fabry disease, muscular dystrophy, hypertrophic obstructive cardiomyopathy, etc.
      • Patients with a history of myocardial infarction within the past three months.
      • Pregnant women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Active comparator
    SGLT2 i TREATMENT

    Drug: SGLT-2 inhibitors

  • Placebo comparator
    PLACEBO

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. LA strain (LASI)

    Using three-dimensional speckle tracking technology to measure longitudinal strain during the reservoir phase (LASr).Using TDI to measure E/e'. The LASI is calculated by these two parameter and can indicate left atrial strain.

    Time frame: from enrollment to the end of treatment at 12 months

Secondary outcomes

  1. circumferential strain (LASr-c)

    Using three-dimensional speckle tracking technology to measure

    Time frame: From enrollment to the end of treatment at 12 months

  2. conduit phase (LAScd)

    Using three-dimensional speckle tracking technology to measure

    Time frame: From enrollment to the end of treatment at 12 months

  3. hospitalization due to heart failure

    Record events of subjects visiting or being hospitalized due to heart failure during the follow-up period. This endpoint includes patients who present with symptoms such as dyspnea, fatigue, and orthopnea during the follow-up period, and have an NT-proBNP level greater than 300pg/ml detected in the emergency department, outpatient clinic, or inpatient department, with a documented diagnosis.

    Time frame: From enrollment to the end of treatment at 12 months

  4. changes in blood pressure

    Patients undergo standardized office blood pressure monitoring (OBPM) using automated oscillometric devices or manual sphygmomanometry with appropriate cuff sizes. Measurements are obtained after 5 minutes of seated rest, with feet flat on the floor and arm supported at heart level. Two to three readings are taken 1-2 minutes apart, and the average is recorded. Take the blood pressure test for every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.

    Time frame: From enrollment to the end of treatment at 12 months

  5. change in blood glucose

    Patients undergo venous blood sampling after 8-12 hours of overnight fasting. Measurements are performed using standardized enzymatic methods (hexokinase or glucose oxidase). HbA1c is measured via high-performance liquid chromatography (HPLC) or immunoassay. FPG monthly; HbA1c every 3 months. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.

    Time frame: From enrollment to the end of treatment at 12 months

  6. Change in lipid metabolism

    Fasting venous blood sampling (12-14 hours overnight fast) followed by Enzymatic colorimetric assays for TC, TG, and HDL-C. Testing is done every month. Ensure that the medication use of the enrolled subjects remains unchanged during the follow-up period.

    Time frame: from enrollment to the end of treatment at 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Mar 19, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482020
Lead sponsor
Huashan Hospital
Responsible party
Yong Li (Clinical Professor, Huashan Hospital) — Principal investigator
First posted
Mar 19, 2026
Start date
Mar 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 19, 2026

Study contacts

Liwen Bao, MD
Contact
blw_betty@163.com
86 13917073226

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SGLT2 inhibitors

Start the discussion